

Das Schwerpunktcurriculum Global Health und das LOEWE-Zentrum DRUID (*Novel Drug Targets against Poverty-related and Neglected Tropical Infectious Diseases*) laden ein:

# ***Adventure and patience on the path to a new drug: The Development of Moxidectin for Onchocerciasis Elimination.***

**Dr. rer. nat. Annette C. Kuesel**  
(TDR Genf)

Dr. Annette C. Kuesel is researcher at the **UNICEF/UNDP/World Bank/WHO Special Programme for Research and Training in Tropical Diseases** (TDR), based in Geneva.

Since 2001, Dr. Kuesel has been involved in the long and challenging research, development and licensing process that eventually led to the approval of moxidectin as the first new treatment for river blindness (onchocerciasis) in 20 years. In her talk, she will share the whole story of moxidectin, from the first drug-discovering activities in the 1990s to registration by FDA (US Food and Drug Administration) in 2018, including clinical trials in endemic areas in the Democratic Republic of Congo, Ghana and Liberia, and an innovative public-private product development partnership between TDR and the not-for-profit company MDGH (Medicines Development for Global Health).

**Mittwoch, 5. Juni 2019**

**18:15 - 19:45 Uhr**

**Medizinisches Lehrzentrum (MLZ), Hörsaal 1, Klinikstraße 29**